Form 8-K - Current report:
SEC Accession No. 0001437749-19-024217
Filing Date
2019-12-11
Accepted
2019-12-11 16:05:46
Documents
4
Period of Report
2019-12-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K navb20191210_8k.htm 8-K 31228
2 EXHIBIT 10.1 ex_167072.htm EX-10.1 107461
3 EXHIBIT 10.2 ex_167073.htm EX-10.2 124269
4 EXHIBIT 99.1 ex_167074.htm EX-99.1 13219
  Complete submission text file 0001437749-19-024217.txt   277478
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

EIN.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35076 | Film No.: 191279875
SIC: 2835 In Vitro & In Vivo Diagnostic Substances